Erratum: A novel aminotetralin-type serotonin (5-HT)2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses (Journal of Pharmacology and Experimental Therapeutics (2014) 349 (310-318) DOI:10.1124/jpet.113.212373)

C. E. Canal; D. Morgan; D. Felsing; K. Kondabolu; N. E. Rowland; K. L. Robertson; R. Sakhuja; R. G. Booth

doi:10.1124/jpet.114.06er14

Erratum: A novel aminotetralin-type serotonin (5-HT)_2C receptor-specific agonist and 5-HT_2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses (Journal of Pharmacology and Experimental Therapeutics (2014) 349 (310-318) DOI:10.1124/jpet.113.212373)

C. E. Canal, D. Morgan, D. Felsing, K. Kondabolu, N. E. Rowland, K. L. Robertson, R. Sakhuja, R. G. Booth

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	533
Number of pages	1
Journal	Journal of Pharmacology and Experimental Therapeutics
Volume	349
Issue number	3
DOIs	https://doi.org/10.1124/jpet.114.06er14
State	Published - Jun 2014
Externally published	Yes

ASJC Scopus subject areas

Molecular Medicine
Pharmacology

Access to Document

10.1124/jpet.114.06er14

Cite this

Canal, C. E., Morgan, D., Felsing, D., Kondabolu, K., Rowland, N. E., Robertson, K. L., Sakhuja, R., & Booth, R. G. (2014). Erratum: A novel aminotetralin-type serotonin (5-HT)_2C receptor-specific agonist and 5-HT_2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses (Journal of Pharmacology and Experimental Therapeutics (2014) 349 (310-318) DOI:10.1124/jpet.113.212373). Journal of Pharmacology and Experimental Therapeutics, 349(3), 533. https://doi.org/10.1124/jpet.114.06er14

Erratum: A novel aminotetralin-type serotonin (5-HT)_2C receptor-specific agonist and 5-HT_2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses (Journal of Pharmacology and Experimental Therapeutics (2014) 349 (310-318) DOI:10.1124/jpet.113.212373). / Canal, C. E.; Morgan, D.; Felsing, D. et al.
In: Journal of Pharmacology and Experimental Therapeutics, Vol. 349, No. 3, 06.2014, p. 533.

Research output: Contribution to journal › Comment/debate › peer-review

Canal, CE, Morgan, D, Felsing, D, Kondabolu, K, Rowland, NE, Robertson, KL, Sakhuja, R & Booth, RG 2014, 'Erratum: A novel aminotetralin-type serotonin (5-HT)_2C receptor-specific agonist and 5-HT_2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses (Journal of Pharmacology and Experimental Therapeutics (2014) 349 (310-318) DOI:10.1124/jpet.113.212373)', Journal of Pharmacology and Experimental Therapeutics, vol. 349, no. 3, pp. 533. https://doi.org/10.1124/jpet.114.06er14

Canal CE, Morgan D, Felsing D, Kondabolu K, Rowland NE, Robertson KL et al. Erratum: A novel aminotetralin-type serotonin (5-HT)_2C receptor-specific agonist and 5-HT_2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses (Journal of Pharmacology and Experimental Therapeutics (2014) 349 (310-318) DOI:10.1124/jpet.113.212373). Journal of Pharmacology and Experimental Therapeutics. 2014 Jun;349(3):533. doi: 10.1124/jpet.114.06er14

Canal, C. E. ; Morgan, D. ; Felsing, D. et al. / Erratum : A novel aminotetralin-type serotonin (5-HT)_2C receptor-specific agonist and 5-HT_2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses (Journal of Pharmacology and Experimental Therapeutics (2014) 349 (310-318) DOI:10.1124/jpet.113.212373). In: Journal of Pharmacology and Experimental Therapeutics. 2014 ; Vol. 349, No. 3. pp. 533.

@article{8f6263220a794ef286a955daf1e4a430,

title = "Erratum: A novel aminotetralin-type serotonin (5-HT)2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses (Journal of Pharmacology and Experimental Therapeutics (2014) 349 (310-318) DOI:10.1124/jpet.113.212373)",

author = "Canal, {C. E.} and D. Morgan and D. Felsing and K. Kondabolu and Rowland, {N. E.} and Robertson, {K. L.} and R. Sakhuja and Booth, {R. G.}",

year = "2014",

month = jun,

doi = "10.1124/jpet.114.06er14",

language = "English (US)",

volume = "349",

pages = "533",

journal = "Journal of Pharmacology and Experimental Therapeutics",

issn = "0022-3565",

publisher = "American Society for Pharmacology and Experimental Therapeutics",

number = "3",

}

TY - JOUR

T1 - Erratum

T2 - A novel aminotetralin-type serotonin (5-HT)2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses (Journal of Pharmacology and Experimental Therapeutics (2014) 349 (310-318) DOI:10.1124/jpet.113.212373)

AU - Canal, C. E.

AU - Morgan, D.

AU - Felsing, D.

AU - Kondabolu, K.

AU - Rowland, N. E.

AU - Robertson, K. L.

AU - Sakhuja, R.

AU - Booth, R. G.

PY - 2014/6

Y1 - 2014/6

UR - http://www.scopus.com/inward/record.url?scp=84901236568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901236568&partnerID=8YFLogxK

U2 - 10.1124/jpet.114.06er14

DO - 10.1124/jpet.114.06er14

M3 - Comment/debate

AN - SCOPUS:84901236568

SN - 0022-3565

VL - 349

SP - 533

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

IS - 3

ER -

Erratum: A novel aminotetralin-type serotonin (5-HT)2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses (Journal of Pharmacology and Experimental Therapeutics (2014) 349 (310-318) DOI:10.1124/jpet.113.212373)

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this

Erratum: A novel aminotetralin-type serotonin (5-HT)_2C receptor-specific agonist and 5-HT_2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses (Journal of Pharmacology and Experimental Therapeutics (2014) 349 (310-318) DOI:10.1124/jpet.113.212373)